References
- Backman JT, Olkkola KT, Aranko K, et al. (1994). Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221–5
- Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
- Brown HS, Wilby AJ, Alder J, et al. (2010). Comparative use of isolated hepatocytes and hepatic microsomes for P450 inhibition studies: transporter-enzyme interplay. Drug Metab Dispos 38:2139–46
- Culm-Merdek KE, von Moltke LL, Gan L, et al. (2006). Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. Clin Pharmacol Ther 79:243–54
- Duan J, Bolger G, Garneau M, et al. (2012) The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans. Antimicrob Agents Chemother 56:5381–6
- Duan J, Yong CL, Garneau M, et al. (2011) Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor. Xenobiotica 42:164–72
- Einolf HJ. (2007). Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37:1257–94
- Fowler S, Zhang, H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 Inhibition: current status on methodologies and their utility for predicting drug–drug interactions. AAPS J 10:410–24
- Grime K, Webborn PJ, Riley RJ. (2008). Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. Drug Metab Dispos 36:1670–8
- Food and Drug Administration (FDA) (2012). Guidance for industry. Drug interaction studies – study design, data analysis and implications for dosing and labeling. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf [last accessed 2 Oct 2012]
- Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. (2001). Pharmacokinetic interactions between nelfenavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45:3445–50
- Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86
- Ito K, Hallifax D, Obach RS, et al. (2005). Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837–44
- Koren G, Zylber-Katz E, Granit L, et al. (1986). Pharmacokinetic studies of nifedipine and digoxin co-administration. Int J Clin Pharmacol Ther Toxicol 24:39–42
- Kosugi Y, Hirabayashi H, Igari T, et al. (2012) Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 42:127–38
- Lam YW, Alfaro CL, Ereshefsky L, et al. (2003). Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluvoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274–82
- Lu C, Berg C, Prakash SR, et al. (2008b). Prediction of pharmacokinetic drug–drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos 36:1261–6
- Lu C, Hatsis P, Berg C, et al. (2008a). Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 36:1255–60
- Lu C, Miwa GT, Prakash SR, et al. (2007). A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome P450 phenotypic data. Drug Metab Dispos 35:79–85
- Luippold AH, Arnhold T, Jörg W, et al. (2011) Application of a rapid and integrated analysis system (RIAS) as a high-throughput processing tool for in vitro ADME samples for liquid chromatography/tandem mass spectrometry. J Biomol Screen 16:370–7
- Mao J, Mohutsky MA, Harrelson JP, et al. (2011). Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 39:591–602
- McGinnity DF, Tucker J, Trigg S, et al. (2005). Prediction of CYP2C9-mediated drug–drug interactions: a comparison using data from recombinant enzymes and human hepatocytes. Drug Metab Dispos 33:1700–7
- Obach RS, Walsky RL, Venkatakrishnan K, et al. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336–48
- Olkkola KT, Ahonen J, Neuvonen PJ. (1996). The effect of systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511–16
- Olkkola KT, Backman JT, Neuvonen PJ. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481–5
- Palkama VJ, Ahonen J, Neuvonen PJ, et al. (1999). Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 66:33–9
- Prueksaritanont T, Vega JM, Rogers JD, et al. (2000). Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects. J Clin Pharmacol 40:1274–9
- Shardlow CE, Generaux GT, MacLauchlin CC, et al. (2011) Utilizing drug–drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39:2076–84
- Veronese ML, Gillen LP, Dorval EP, et al. (2003). Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol 43:1091–100
- Wong SG. (2011). Prediction of drug-drug interactions arising from mechanism-based inactivation: key input parameters and impact on risk assessment. Curr Drug Metab 12:871–90